Question 1

What specific treatments will I receive during this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer clinical trial (NCT03916419). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options I might have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer clinical trial (NCT03916419). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer clinical trial (NCT03916419). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer clinical trial (NCT03916419). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will be required before and during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer clinical trial (NCT03916419). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with the MRI imaging involved in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer clinical trial (NCT03916419). Contact the study team or your healthcare provider for specific answers.

What this study is about